title: [A case of peritoneal metastasis of gastric cancer responding to TS-1, administered for four consecutive weeks with two-week rests].
abstract: We treated a patient with gastric cancer considered to be unresectable due to peritoneal metastasis, who responded remarkably to treatment with TS-1. The patient was a 62-year-old male. His diagnosis was gastric cancer, for which he underwent surgery on February 22, 2001. Laparotomy disclosed many nodules measuring 2-3 mm in diameter in the abdominal cavity, so rapid pathological tests were conducted during the operation. The test results indicated peritoneal metastasis from gastric cancer. Therefore, simple laparotomy was employed as the best option. On day 13 after surgery, oral administration of TS-1, bid., at a daily dose of 120 mg was commenced. In our outpatient clinic, he was given 3 courses, each comprising 4 weeks' medication and 2 weeks' discontinuation. Subsequently, upper digestive tract endoscopy was performed but only scars in the gastric vestibular area were observed. Biopsy could not detect any malignant findings. Medication was discontinued due to the patient's preference and he died of gastric cancer 10 months after operation.
authors.affiliation: Dept. of Surgery, Osaka Rosai Hospital.
authors.forename: Yoshihisa
authors.initials: Y
authors.lastname: Naka
authors.forename: Kiyoshi
authors.initials: K
authors.lastname: Yoshikawa
authors.forename: Riichiro
authors.initials: R
authors.lastname: Nezu
authors.forename: Masahiro
authors.initials: M
authors.lastname: Fujikawa
authors.forename: Makoto
authors.initials: M
authors.lastname: Fujii
authors.forename: Takashi
authors.initials: T
authors.lastname: Emoto
authors.forename: Yasuhiko
authors.initials: Y
authors.lastname: Yoshioka
authors.forename: Takamitsu
authors.initials: T
authors.lastname: Komaki
authors.forename: Takenori
authors.initials: T
authors.lastname: Yokota
authors.forename: Iki
authors.initials: I
authors.lastname: Adachi
authors.forename: Asahiro
authors.initials: A
authors.lastname: Kamei
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy* / Q000556:secondary*; D000284:Administration, Oral; D000964:Antimetabolites, Antineoplastic / Q000627:therapeutic use*; D004338:Drug Combinations; D006801:Humans; D008297:Male; D008875:Middle Aged; D010094:Oxonic Acid / Q000627:therapeutic use*; D010534:Peritoneal Neoplasms / Q000556:secondary*; D011725:Pyridines / Q000627:therapeutic use*; D013274:Stomach Neoplasms / Q000188:drug therapy* / Q000473:pathology; D005641:Tegafur / Q000627:therapeutic use*
chemical_list: D000964:Antimetabolites, Antineoplastic; D004338:Drug Combinations; D011725:Pyridines; C079198:S 1 (combination); D005641:Tegafur; D010094:Oxonic Acid